logo

Clinical Trial Calendar

Share
Company Name Regenxbio Inc
Event Name Preliminary safety and tolerability data from Phase I/II trial of RGX-501
Indication Homozygous familial hypercholesterolemia
Outcome Date
Outcome
Result Date before Q1 2018
News
http://ir.regenxbio.com/phoenix.zhtml?c=254175&p=irol-newsArticle&ID=2315561
Return to Clinical Trial Calendar